Fiserv stock edges up as Clover lands CareCredit expansion — here’s what traders watch next

Fiserv stock edges up as Clover lands CareCredit expansion — here’s what traders watch next

New York, January 14, 2026, 15:08 EST — Regular session

  • Fiserv shares edged up roughly 0.1% in afternoon trading, holding firm against the wider market downturn
  • Synchrony broadened CareCredit’s reach by integrating it further with Fiserv’s Clover platform, now covering over 40,000 providers
  • Investors are eager for the next confirmed earnings date and any news on the turnaround

Fiserv shares edged up Wednesday afternoon, hitting $66.81, even as the S&P 500 ETF slipped roughly 0.8%.

The move was modest, yet the situation remains fragile. Fiserv is working to regain trust after slashing its outlook and shaking up leadership in October, which sparked a record one-day plunge in its stock.

Broader markets dragged lower again. Wall Street’s key indexes dropped for a second day while investors digested patchy results from major banks. “It’s not unusual to see a little bit of a pullback,” said Jake Johnston, deputy CIO at Advisors Asset Management. 1

A company-linked headline lingered in the background. On Monday, Synchrony announced it expanded its CareCredit integration with Clover, Fiserv’s point-of-sale and commerce platform, now covering more than 40,000 health and wellness providers. The upgrade enables the entire financing process—from application to payment—directly on Clover devices. Synchrony executive Beto Casellas called it a “powerful operational advantage.” Fiserv’s Katie Whalen added the partnership should help practices “streamline payment processes and enhance the patient experience.” 2

Payments stocks showed a mixed picture. PayPal gained roughly 1.6%, but Global Payments dipped 0.3%, and Fidelity National Information Services dropped close to 0.9%.

Fiserv came into Wednesday following a rough day. On Tuesday, the stock dropped 2.13% amid a broader market pullback, mirroring a selloff among other payments companies.

The downside remains clear. Financial stocks have felt the heat from policy shifts and rate news, especially concerns over a proposed cap on credit-card interest rates. That’s rattling confidence in consumer-linked payment volumes.

Investors are waiting for Fiserv to announce its next concrete milestone. The company’s investor relations page shows no scheduled events at the moment. 3

Fiserv’s next earnings report is tentatively set for around Feb. 4, according to some calendars, but the company hasn’t officially confirmed a date. Investors will be watching that release closely, especially for any updated guidance. 4

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline
Previous Story

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Constellation Software stock tumbles to new 52-week low as investors question acquisition-led growth
Next Story

Constellation Software stock tumbles to new 52-week low as investors question acquisition-led growth

Go toTop